Brief: Infinity Pharma Reports Data From Front-Line Triple Negative Breast Cancer Cohort From Ongoing Trial
09/12/2020 14:15
Dec 9 (Reuters) - Infinity Pharmaceuticals Inc INFI.O :
* INFINITY PHARMACEUTICALS - ANNOUNCED THAT DATA FROM
FRONT-LINE
TRIPLE NEGATIVE BREAST CANCER (TNBC) COHORT FROM ONGOING MARIO-3
CLINICAL TRIAL
* INFINITY PHARMACEUTICALS INC - EXPECTS TO COMPLETE
ENROLLMENT IN
MARIO-3 IN MID-2021
Source text for Eikon: ID:nBw5Q71Vha
Further company coverage: INFI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Infinity Pharmaceuticals
See all newsBrief: Infinity Pharmaceuticals Filed Voluntary Petition For Relief Under Provisions Of Chapter 11
Brief: Infinity Pharmaceuticals Inc Received Determination Letter From Nasdaq On September 12
Brief: Infinity Pharma Says On Sept 5, 2023, Co Received Letter From Nasdaq Notifying That Listing Of Common Stock Was Not In Compliance With Nasdaq Listing Rule
Brief: Infinity Pharmaceuticals Approved Plan To Reduce Co's Overall Headcount By 21 Positions
U.S. STOCKS ON THE MOVE-General Motors, Estee Lauder, IMAX